Aimo A, Giannoni A, Castiglione V, et al. Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. Eur J Prev Cardiol. 2017; 24: 1718–1724.
2.
FinstererJGelpiEStöllbergerC. Left ventricular hypertrabeculation/noncompaction as a cardiac manifestation of Duchenne muscular dystrophy under non-invasive positive-pressure ventilation. Acta Cardiol2005; 60: 445–448.
3.
FinstererJStöllbergerCSchubertB. Acquired left ventricular hypertrabeculation/noncompaction in mitochondriopathy. Cardiology2004; 102: 228–230.
4.
StöllbergerCFinstererJBlazekG. Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. Am J Cardiol2002; 90: 899–902.
5.
FinstererJ. Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction. Pediatr Cardiol2009; 30: 659–681.
6.
FinstererJStöllbergerCFazioG. Neuromuscular disorders in left ventricular hypertrabeculation/noncompaction. Curr Pharm Design2010; 16: 2895–2904.
7.
FinstererJKothariS. Cardiac manifestations of primary mitochondrial disorders. Int J Cardiol2014; 177: 754–763.
8.
FinstererJStöllbergerC. Heart disease in disorders of muscle, neuromuscular transmission, and the nerves. Korean Circ J2016; 46: 117–134.
9.
FinstererJStöllbergerCBergerE. Beneficial effect of ivabradine in dilated cardiomyopathy from Becker muscular dystrophy. Herz2012; 37: 702–705.
